<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Taba">
 <table frame="hsides" rules="groups">
  <tbody>
   <tr>
    <td align="left">Direct in vivo delivery of synthetic nucleic acid-encoded antibodies employing plasmid DNA [plasmid DNA-encoded monoclonal antibodies (pDNA-mAbs)] and messenger RNA-encoded monoclonal antibodies (mRNA-mAbs) platforms represent new approaches for the in vivo delivery of antibody-like biologics.</td>
   </tr>
   <tr>
    <td align="left">While there are more preclinical data using pDNA-mAbs, both platforms have made significant progress and are demonstrating promising efficacy in infectious disease and cancer studies in small and large animal models.</td>
   </tr>
   <tr>
    <td align="left">These platforms have advantages such as rapid product development and simpler manufacturing processes, yet they represent different strategies for deployment, with unique advantages and challenges.</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
